Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies.

@article{Averill2017GlutamateDA,
  title={Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies.},
  author={Lynnette A. Averill and Prerana Purohit and Christopher L. Averill and Markus A Boesl and John H. Krystal and Chadi G. Abdallah},
  journal={Neuroscience letters},
  year={2017},
  volume={649},
  pages={
          147-155
        }
}
Posttraumatic stress disorder (PTSD) is a chronic and debilitating psychiatric disorder afflicting millions of individuals across the world. While the availability of robust pharmacologic interventions is quite lacking, our understanding of the putative neurobiological underpinnings of PTSD has significantly increased over the past two decades. Accumulating evidence demonstrates aberrant glutamatergic function in mood, anxiety, and trauma-related disorders and dysfunction in glutamate… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS